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SUMMARY
 
The debate on whether infection precipitates or prevents auto-
immunity remains a contentious one. Recently the suggestion
that some unknown microbe can be at the origin of some chronic
inﬂammatory diseases has been countered by accumulating
evidence that decreasing infection rates might have an
important role to play in the rising prevalence of autoimmune
disorders. The ‘Hygiene Hypothesis’ was initially postulated
to explain the inverse correlation between the incidence of
infections and the rise of allergic diseases, particularly in the
developed world. Latterly, the Hygiene Hypothesis has been
extended to also incorporate autoimmune diseases in general.
Amongst the various infectious agents, a particular emphasis
has been put on the interaction between parasitic worms and
humans. Worm parasites have co-evolved with the mammalian
immune system for many millions of years and during this time,
they have developed extremely effective strategies to modulate
and evade host defences and so maintain their evolutionary
ﬁtness. It is therefore reasonable to conclude that the human
immune system has been shaped by its relationship with
parasitic worms and this may be a necessary requirement for
maintaining our immunological health. Fully understanding
this relationship may lead to novel and effective treatments for
a host of deleterious inﬂammatory reactions.
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INTRODUCTION
 
The last three decades have witnessed a dramatic increase
in the incidence of autoimmune inﬂammatory diseases in
developed countries, including type 1 diabetes (T1D),
multiple sclerosis (MS), rheumatoid arthritis (RA), and Crohn’s
disease, to name but a few (1,2). Autoimmune disease is
characterized by an immune-mediated attack on a target organ
that it is no longer recognized by the immune system as self.
Autoimmune pathology can be caused by both antibody and
cell-mediated components. Predisposition to autoimmunity is
under polygenic control, but studies on identical (monozy-
gotic) twins demonstrate that environmental factors might
be equally important (3,4). The rising trend in autoimmune
diseases looks set to continue and the projected incidences
over the next 30 years are potentially catastrophic. The countries
that have seen the most pronounced rise in autoimmunity
have over the same period seen tremendous improvements in
sanitation and socioeconomic status. Moreover, the steady
migration from rural to urban areas has dramatically reduced
childhood exposure to infectious organisms. Rapid anthro-
pogenic transformation of the environment and life style has
not allowed time for the human immune system to adjust to
these changes. The very characteristics of the immune system
that had previously been so advantageous for combating
infections might now be the principal contributing factor for
the increasing prevalence of autoimmune disease. Improve-
ments in living conditions and the reduced exposure to
childhood infections in particular, have been suggested to
contribute to the increase in atopy and autoimmunity (5). This
so-called 
 
Hygiene Hypothesis
 
 has, in recent years, attracted
interest and controversy in equal measure. Epidemiological
data from the World Health Organization (WHO) largely
support the hypothesis, indicating that autoimmune inﬂam-
matory diseases like T1D and MS are extremely rare in most
African and Asian populations, yet increase conspicuously
when these same populations migrate to a modern setting
(6,7). In this piece we will review the evidence for the Hygiene
Hypothesis particularly with regard to parasitic worm
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(helminth) infections and consider any potential therapeutic
avenues that it may prescribe.
 
INFECTIOUS DISEASE, AUTOIMMUNITY, 
AND THE HYGIENE HYPOTHESIS
 
The Hygiene Hypothesis suggests that parasites and microbes
have been important for shaping and tuning the evolution of
the human immune system (8). According to this hypothesis, the
immune system is in a state of preparedness, primed to repel the
pathogen assaults that characterized the lot of humanity for
most of its existence. In developed countries industrialization
has strongly contributed to human migration from rural areas
to the cities. One of the consequences of resettlement has been
the removal of people from the pathogen-replete ecosystems
in which their immune systems had adapted since prehistory.
Sanitation, and access to clean food and water became a common
life standard for most individuals in the developed world. Addi-
tionally, following the Second World War the use of antibiotics
became commonplace, dramatically altering exposure to
bacterial pathogens. The fact that infections were no longer
prevalent has led to the emergence of autoimmune inﬂam-
matory diseases. This suggests that parasites, if not actually
preventing autoimmunity 
 
per se
 
, at least divert the immune
system to the more productive cause of limiting tissue pathology.
Parasites themselves wield an astonishing array of mechanisms
to evade the ravages of the host’s immune system and in so doing
ameliorate the more self-destructive aspects of a response.
Industrialized countries are indeed experiencing an increase
in autoimmune diseases. A very different picture is present in
developing countries. Because of limited economic resources,
health aid organizations tend to focus more on the three so-
called ‘Big Killer Diseases’; HIV, malaria and tuberculosis.
As a consequence, six neglected infectious diseases with
low mortality rates such as ﬁlariasis, leprosy, onchocerciasis,
schistosomiasis, soil-transmitted helminths, and trachoma,
are still widespread yet autoimmune inﬂammatory diseases
are virtually absent (WHO and International Diabetes Feder-
ation databases) (see Figure 1). Loss of parasite colonization
in those individuals living in developed countries has had a
unique impact on our immune response and, together with
genetic predisposition, is probably the pre-eminent factor
contributing to the development of autoimmune disease  (9–12).
T1D occurs equally among males and females and is more
common in whites than in non-whites. Data from the IDF
(International Diabetes Federation) database indicate that
T1D is rare in most African and Asian populations. Conversely,
some northern European (Finland and Sweden) and northern
American countries, have high rates of T1D. Over a million
people worldwide have MS and this incidence also appears to
be increasing. Onset of symptoms typically occurs between the
ages of 15 and 40 years, with a peak incidence in people in their
20s and 30s, and women are affected twice as often as men. MS
occurs worldwide but is most common in Caucasian people of
northern European origin. It is extremely rare among Asians
and Africans (13). Crohn’s disease also occurs most frequently
among North Europeans and North Americans. Although the
disorder can begin at any age, its onset principally occurs between
15 and 30 years of age. There appears to be a familial aggregation
of patients with Crohn’s disease such that 20–30% of patients
with Crohn’s disease have a family history of inﬂammatory
bowel disease.
 
T1D AS AN EXAMPLE OF AN 
INFLAMMATORY AUTOIMMUNE DISEASE
 
T1D is an autoimmune condition characterized by a
progressive cellular inﬁltration of the pancreas resulting in
Figure 1 Inverse correlation between Type 1 
Diabetes (T1D) and ‘neglected infectious 
diseases’. Red delineates areas which 
harbour six or more of the low mortality 
neglected diseases (ﬁlariasis, leprosy, 
onchocerciasis, schistosomiasis, 
soil-transmitted helminths, and trachoma). 
Yellow delineates areas where there are 
relatively high incidences of T1D (> 8 per 
100 000/year). Non coloured areas delineate 
where T1D < 8 per 100 000/year and where 
the ‘neglected diseases’ are not endemic. 
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the destruction of insulin-producing cells. Since insulin
regulates glucose uptake into cells from the circulation, its
deﬁciency is responsible for glucose accumulation in the
blood and ensuing cell starvation (hyperglycaemia, coma, etc.).
T1D was considered a death sentence until the early 1920s,
when pancreatic extracts were used to correct hyperglycaemia
(14). This discovery led to the availability of an effective
treatment – insulin injections – and the ﬁrst clinical patient
was treated in 1922. Despite the substantial technological
improvement for monitoring glycaemia, relatively little progress
has been made in terms of therapy; to date, insulin injection
remains the only dependable treatment.
T1D is an autoimmune polygenic disorder, with numerous
gene loci contributing to susceptibility. Historically, the ﬁrst
genes associated with T1D were the Human Leukocyte
Antigens (HLA) on chromosome 6, in particular the DR
and DQ class II regions (15,16). There remains controversy
about the relative contributions of DR and DQ on T1D
susceptibility with some studies supporting a stronger
association for the DQ locus and a secondary role for DR (17).
Recently, other genes outside the HLA complex have been
associated with predisposition to T1D, including cytotoxic
T lymphocyte associated antigen 4 (CTLA-4) and lymphoid
tyrosine phosphatase (PTPN22) (18).
As mentioned above, genetic components affect the
propensity for T1D but the environment appears to play a
fundamental role in regulating the onset of the disease. Many
different intercepting factors must be taken into account.
Within the Caucasian population the incidence of T1D varies
between nations. For example Scandinavian countries have
the highest incidence of T1D in Europe, whereas relatively
under-developed countries like Albania and Romania have
some of the lowest (see Table 1). However, these statistics need
to be considered in the context of genetics, i.e. the relatively
limited genetic diversity seen in Scandinavia (particularly
Finland) overlaying and possibly synergizing with the effects
of a hygienic environment. Interestingly in Europe, countries
with a more agriculture-based economy have lower incidences
of T1D (19). This suggests that exposure of the population
to a diet containing fewer processed foods and more direct
contact with animal-transmitted pathogens such as 
 
Salmonella
 
could be a relevant factor in preventing T1D. The North–
South gradient also seems to play a role in diabetes incidence.
Indeed in Southern European countries the lower socio-
economic status and higher temperatures might predispose
the inhabitants to infections and contribute to the lower
frequency of T1D. Two of the largest islands in the Mediter-
ranean, Sicily and Sardinia, present an interesting contrast
in T1D incidence and the effects of genetics. These islands
are located at similar latitudes and bio-geographical zones,
yet Sicily has a low incidence of T1D whereas Sardinia has
one of the highest in the world, indicative of a strong genetic
modiﬁer (20). If we look now at countries outside Europe
(and/or North America) we can see that the inverse correla-
tion between poverty and T1D is even more pronounced.
Poor sanitation and prevalence of infections seem to protect
the inhabitants of developing countries from autoimmune
diabetes (see Table 1). A good example is the interdependence
between access to clean water, and diseases such as T1D
(Figure 1). Indeed many parasitic diseases such as Schisto-
somiasis require a freshwater environment for transmission.
Overall these considerations strongly suggest that the
continuous improvement in sanitation and living standards
in developed countries is a key factor for the increase of T1D.
According to the IDF database the global incidence of T1D
in children and adolescents is increasing, with an estimated
overall annual rate of about 3%. Before the 1920s childhood
diabetes, although uncommon, was rapid and fatal, therefore
it could be argued that the introduction of insulin treatment
contributed to a subtle increase in the frequency of T1D
susceptibility genes. That said, the dramatic rise of T1D in
children under 14 years of age in developed countries cannot
be explained by genetic factors alone. The T1D epidemic
observed over the last 50 years in Western Europe and North
America is predicted to plateau. For example, Norway
showed no increase over the last decade (21). The high T1D-
incidence areas (with the exception of Finland) in Europe
appear to have reached a plateau, but the overall trend is still
rising in ex-Eastern Bloc countries and in the Middle East,
particularly in Kuwait (22–24). Since changes in the environ-
ment seem to play a more signiﬁcant role, predications are
that childhood diabetes will not increase exponentially in
the high incidence areas but will rather take place in those
countries that are gradually seeing an improvement in their
living standards and hygiene. For instance, the projections for
diabetes incidence in the year 2025 predict a sharp increment
in diabetes in the Middle East, South America, Mexico, and
South East Asia (see Table 2).
 
ANIMAL MODELS OF HUMAN 
AUTOIMMUNE DISEASE: THE NOD MOUSE 
AND 
 
SCHISTOSOMA MANSONI
 
 INFECTION
 
Since the 1970s the NOD (Non-Obese Diabetic) mouse
has provided a good model for the study of T1D. Initially
generated in Japan by Makino and co-workers, the NOD
mouse has became one of the most popular models to study
T1D (25). NOD mice spontaneously develop T1D, with
features similar to the human disease. NOD T1D is under
polygenic control and, much like the human disease, associates
with particular Class II major histocompatibility (MHC)
polymorphisms (26). The pancreas of NOD mice become
inﬁltrated with mononuclear cells around 6 weeks of age, with
cells appearing chieﬂy around the islets and pancreatic ducts. 
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By 8–12 weeks of age the inﬁltrate progresses to the islets,
causing destruction of the 
 
β
 
 cell mass. Pathology is primarily
cell-mediated, with dendritic cells (DC), macrophages (M
 
Φ
 
)
and B cells responsible for the initiation of the autoimmune
process by presentation of pancreatic antigen and secretion
of inﬂammatory mediators (27,28). Subsequently, CD8+ and
CD4+ T cells enter the pancreas, inﬁltrate the islet area and
 
β
 
 cell destruction arises through a Th1-mediated immune
response (29) (Figure 2). After 12 weeks of age the clinical signs
of disease start to manifest with polydypsia and glycosuria
and by the age of 30 weeks 80–100% of female mice are
diabetic. NOD mice show a distinct gender difference with
female NOD mice developing T1D at a much higher incidence
than the males (10–20%). There are variations between
colonies and the conditions under which NOD mice are
kept appear to greatly inﬂuence the rate and frequency of
onset of diabetes. It rapidly became clear that NOD mice
kept under germ-free conditions developed diabetes at a
much faster rate and higher incidence than mice kept under
conventional conditions (30). This observation, made
independently in many different laboratories, provoked
immunologists to consider the possibility that infection
and/or exposure to microbial products was responsible for
the reduction of T1D incidence in some animal colonies.
Experiments designed to test this hypothesis and elucidate
the mechanisms of T1D prevention, revealed that infections
Table 1 Inverse correlation between Type 1 diabetes (T1D) and hygiene conditions
 
Country
T1D incidence 
per thousand, 
0–14 yrs
Sanitation (% of 
households without 
access to improved 
sanitation)
H2O (% of 
households with 
access to improved 
H2O supply)
Low mortality 
infectious 
neglected diseases 
(prevalence)
Europe
Finland 37·4 0 100 Absent
Sweden 28 0 100 Absent
UK 18·9 0 100 Absent
Romania 5 47 58 Absent
Albania 3·6 9 97 Absent
North America
USA 13·8 0 100 Absent
Canada 24·1 0 100 Absent
Africa
Tanzania 0·9 10 68 Endemic
Ghana No data 28 73 Endemic
Western Paciﬁc
China 0·6 60 75 Frequent
Vietnam 0·3 53 77 Frequent
Singapore 2·5 0 100 Rare/Absent
Australia 17·8 0 100 Rare/Absent
New Zealand 15·2 0 100 Rare/Absent
East Mediterranean and Middle East
Egypt 8 2 97 Rare/Absent
Saudi Arabia 12·3 0 95 Rare/Absent
Kuwait 20·9 No data No data Rare/Absent
Yemen 2·5 62 69 Endemic
Afghanistan 1·2 88 13 Frequent
South/Central America
Brazil 8 24 87 Endemic
Argentina 6·4 18 94 Rare/Absent
Venezuela 0·1 32 83 Rare/Absent
Peru 0·4 29 80 Rare/Absent
South East Asia
India 4·2 72 84 Endemic
Nepal 0·6 72 88 Endemic
Bangladesh 4·2 52 97 Endemic
Broadly-speaking there is an inverse relationship between the incidence of T1D and hygiene as gauged by levels of sanitation, access to clean 
water, and the presence of low mortality infectious diseases (ﬁlariasis, leprosy, onchocerciasis, schistosomiasis, soil-transmitted helminths, and 
trachoma). Adapted from the IDF e-Atlas, http://www.eatlas.idf.org/, © International Diabetes Federation, Brussels. 
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triggering both Th1- and Th2-like responses could delay or
abolish autoimmune pathology in NOD mice (see Table 3).
The NOD mouse appears to be a good model for testing
the predictions of the Hygiene Hypothesis, therefore we
have used it to study the effects of bacterial and helminth
infection on the onset of T1D. 
 
Schistosoma mansoni
 
 infection,
or even exposure to antigens derived from this helminth,
results in long-lasting prevention of diabetes characterized
by  a strong Th2 response (31,32). 
 
S. mansoni
 
  protection
appears to stem largely from a shift to a non-pathological Th2
response, although there is also evidence for the generation of
immunosuppressive regulatory cells (Treg) (32). Essentially
similar results have been observed using two other species of
helminth, 
 
Heligmosomoides polygyrus
 
 and 
 
Trichinella spiralis
 
(C. Lawrence, unpublished data). Similarly, infection of NOD
mice with live attenuated 
 
Salmonella
 
 bacteria induces a
long-lasting protection from T1D (35). Prevention of a Th1-
mediated autoimmune disease such as T1D by infection with
a classic Th1-stimulating pathogen appears rather paradoxical.
Potentially a generalized 
 
Salmonella
 
-induced IFN-
 
γ
 
 release
may mediate suppression through its effects on the innate
immune system, particularly DC, but the mechanism awaits
full characterization (our unpublished observations). At any
rate, the invocation of a simple Th1 to Th2 shift is unable
to explain all the immunomodulatory effects of microbial
infection that lead to prevention of T1D, and may instead
require a more complex paradigm incorporating, for example,
the action of Treg.
 
HELMINTH MODULATION OF THE IMMUNE 
SYSTEM
 
Amongst the various infectious agents, helminth parasites
are regarded as master manipulators of the host immune
Table 2 Diabetes (Type 1 and 2) incidences by region for the year 2003 and projected incidences for the year 2025 (Type 1 and type 2). 
Ages 20–79
 
Region
2003 2025
Population 
(million)
No. of people with 
diabetes (million)
Prevalence 
(%)
Population 
(million)
No. of people with 
diabetes (million)
Prevalence 
(%)
Europe 621 48·4 7·8 646 58·6 9·1
North America 290 23·0 7·9 374 36·2 9·7
Africa 295 7·1 2·4 541 15·0 2·8
Western Paciﬁc 1384 43·0 3·1 1751 75·8 4·3
East Mediterraneanand Middle East 276 19·2 7·0 494 39·4 8·0
South and Central America 252 14·2 5·6 364 26·2 7·2
South East Asia 705 39·3 5·6 1081 81·6 7·5
Total 3823 194 5·1 5251 333 6·3
Adapted from the IDF e-Atlas, http://www.eatlas.idf.org/, © International Diabetes Federation, Brussels.
Figure 2 Immunoﬂuorescent staining of a NOD pancreas 
showing mononuclear cell inﬁltration. Section of NOD 
pancreas showing insulin producing β cell mass (orange) and 
mononuclear cells (green) stained with CD3. Pancreas from 
young mice show no inﬁltrate whereas (a) older mice show 
a spontaneous inﬁltration around the islet (b) initiating 
β cell destruction. 
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system, often inducing a long-lasting asymptomatic form of
infection (37,38). Parasitic worms can establish and reproduce
in mammalian hosts, switching off the inﬂammatory immune
response and inducing a tolerant response to parasite antigens.
Following encounter with 
 
S. mansoni
 
  antigens, profound
changes are observed in the innate immune system of the
host, including modiﬁcation of DC, M
 
Φ
 
, and NKT cells,
phenotype and cytokine secretion (39,40). 
 
S. mansoni
 
 antigens
can induce the secretion of regulatory cytokines from these
cells as well as B1 B cells (41), resulting in the expansion of
Th2 and Treg populations that might be responsible for
maintaining self-tolerance (42–45) (see Figure 3). DC and
M
 
Φ
 
 are fundamental to directing immune responses along
either a tolerating or activating pathway, therefore it is not
surprising that helminths have evolved strategies targeting
receptors on these cells. Toll like receptors (TLRs) and C-
type lectin receptors (CLRs), broadly expressed on DCs and
M
 
Φ
 
s, are the main parasite targets for evading immuno-
surveillance (46). More speciﬁcally, glycosylated molecules
(expressed and secreted by 
 
S. mansoni
 
) bind to the CLR and
antagonize a TLR pro-inﬂammatory pathway (47). Numerous
studies have shown that 
 
S. mansoni
 
 products induce IL-10
production by DCs and have a direct anti-inﬂammatory effect
on DCs by controlling TLR ligand-induced DC maturation
(48). 
 
S. mansoni
 
 has also been shown to induce alternatively
activated M
 
Φ
 
, which secrete small amounts of inﬂammatory
mediators and inhibit T cell proliferation (49).
The inﬂuence of helminth products on the innate immune
system is not just restricted to DCs. Depending on the nature
of the pathogen, NKT cells can direct the immune response
in an appropriate direction by secreting a wide variety of
pro- and anti-inﬂammatory cytokines (50). Schistosomes
are rich in glycosylated molecules, which heavily decorate
their integument or are actively secreted, and glycolipids
presented by CD1d (a non-classical MHC molecule) on
antigen presenting cells (APCs) may thus be able to activate
regulatory NKT cells (51).
One of the most obvious and well-documented responses
to 
 
S. mansoni
 
 is the Th2 dominance in the T cell population.
Any initial Th1 response to the parasite is quickly redirected
to a state of quiescence (52). The cytokine environment is
fundamental for this purpose: large amounts of IL-4, IL-5 and
IL-13 are secreted from the T cell pool, reinforcing not just
T cell polarization, but also the anti-inﬂammatory loop on
DC and M
 
Φ
 
 (32). The parasite is also capable of containing
the side-effects of such a strong Th2 response, inducing the
secretion of IL-10 and TGF-
 
β
 
 by other T cell subtypes (53,54).
For example, animals and humans infected or exposed to
 
S. mansoni
 
 antigens do not automatically develop allergies
at a higher incidence (see Figure 3). The 
 
de novo
 
 induction
and/or the expansion/recruitment of Treg almost certainly
underlies the ability of many parasites to both evade a
sterilizing immune response and also suppress both Th1 and
Th2 arms of the adaptive immune system (55,56).
 
THERAPEUTIC APPLICATION OF PARASITE 
PRODUCTS AND FUTURE PROSPECTS
 
Helminths are exquisitely adapted to evading and modulating
the mammalian immune response; and interestingly similar
evasion mechanisms can be shared among distantly related
species (see Table 4).
This begs the obvious question of whether this ability can
ever be exploited for therapeutic purposes. The growing body
of epidemiological and experimental data detailed above
strongly suggests that a reduction in helminth infection is
linked to rising rates of autoimmunity and atopy. This offers
the real possibility that helminths applied in a controllable
clinical setting, could relieve inﬂammatory disease yet
minimize the adverse effects of the parasite. Indeed, several
models of autoimmune disease have validated the potential
of such an approach. Although still a very young ﬁeld,
limited clinical trials have already been carried out assessing
the effects of the porcine whipworm, 
 
Trichuris suis
 
, on IBD
Table 3 Infectious agents or their products that prevent T1D in NOD mice
 
Agent or product Th1/Th1 bias Reference
Schistosoma mansoni Th2 (31)
Schistosoma mansoni eggs Th2 (32)
Schistosoma mansoni soluble worm antigen (SWA) Th2 (32)
Schistosoma mansoni soluble egg antigen  (SEA) Th2 (32)
Heligmosomoides polygyrus Th2 C. Lawrence, unpublished data
Trichinella spiralis Th2 C. Lawrence, unpublished data
Mycobacterium bovis Th1 (33)
Mycobacterium avium Th1 (34)
Salmonella typhimurium  Th1 (35)
Mouse hepatitis virus (MHV) Th1 (36) 
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(Inﬂammatory Bowel Disease) (65). Initial pilot studies
using oral ingestion of live 
 
T. suis
 
 ova at regular intervals
hinted at a beneﬁcial effect on IBD without any overt side-
effects (62). Larger trials, including one double-blinded and
placebo controlled, revealed effective relief of Crohn’s disease
in nearly 80% of patients but much more modest effects in
the case of Ulcerative Colitis (62,66). It should be noted
that the patients enrolled in these studies were refractory to
standard interventions, so any beneﬁcial effect should be
welcomed, but larger trials with improved clinical scoring
would be desirable (67). A similar trial, this time using the
human hookworm 
 
Necator americanus
 
, is also being carried
out in Crohn’s patients (68). The caveat of a live parasite
approach is only too evident; even if the chosen parasite is
unable to productively infect the host patient, as is the case
with 
 
T. suis
 
, there may still be some adverse side-effects,
particularly when patients are challenged in conjunction with
immunosuppressants, or in otherwise immunosuppressed
individuals. In particular, parasite-mediated immunomo-
dulation may compromise the anti-tumour responsiveness of
the patient (69–71). Far more desirable then would be to mimic
the beneﬁcial effects of helminth infection by using non-
infective products derived from them. Aside from the safety
issues, the use of helminth products or their synthetic analogues
Figure 3 S. mansoni modulation of the 
immune response. S. mansoni live helminth 
and antigens modify cells of the innate 
immune system through interaction with 
TLRs and CLRs arresting the production 
inﬂammatory mediators and eliciting 
instead, the release of immunoregulatory 
cytokines such as IL-10. This results in the 
generation of suppressive Treg and a bias 
towards a Th2 response. aaMΦ; alternately 
activated macrophage.
Table 4 Helminth infection or helminth products that prevent autoimmunity in animal models
 
Agent or product Autoimmune disease Reference
Schistosoma mansoni Experimental autoimmune encephalomyelitis (57)
Graves’ thyroiditis (58)
Schistosoma mansoni eggs Experimental autoimmune encephalomyelitis  (59)
Experimental colitis (60)
Trichinella spiralis  Experimental colitis (61)
Trichuris suis Inﬂammatory bowel disease (62)
Heligmosomoides polygyrus Experimental colitis (63)
ES-62 (Acanthocheilonema viteae product) Collagen-induced arthritis (64)
Infection with live helminth or challenge with their products (antigens, eggs etc.) can delay or prevent the induction of autoimmune disease 
in various disease models. 
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may also allow a ﬁner level of immunomodulatory control
or even potency. Emerging proteomics data and the steady
progress in the 
 
S. mansoni
 
 sequencing project will also surely
illuminate the search for novel and efﬁcacious immuno-
modulatory helminth-derived products (72,73).
One prediction of the Hygiene Hypothesis is that the
rising rate of inﬂammatory disorders is due speciﬁcally to a
paucity of infection during infancy, which in turn tunes the
immune response in subsequent adulthood to a less patho-
genic modality. This being the case, therapeutic dosing of a
helminth (or products thereof ) to relieve fulminant inﬂam-
matory disease in an adult may be relatively ineffective. The
patient’s immune repertoire, both adaptive and innate, has
already been shaped by the absence of parasite antigens, and
is subject to only relatively minor perturbations. This may
explain the incomplete effects of the 
 
T. suis
 
 infections described
above.  A prolonged treatment regimen, infection with an
attenuated host-speciﬁc helminth, or exposure during the
supposed critical period of infancy may all potentially improve
the efﬁcacy of such an approach. In some not too distant
futurity, there may come a day when we all take ‘helminth
supplements’ along with our Omega 3 fatty acids, vitamins,
and whatever else goes to make up a modern balanced diet.
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